Stay updated on Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial
Sign up to get notified when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.

Latest updates to the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page
- Check2 days agoChange DetectedAdded a dedicated Locations section listing California, Massachusetts, New Jersey, New York, and Pennsylvania; updated the page revision to v3.3.3 and removed the HHS Vulnerability Disclosure and the individual state location entries.SummaryDifference0.5%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no study content or site functionality has changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check37 days agoChange DetectedRemoved the site-wide notice about a lapse in government funding and NIH operating status. The core study information on the page remains unchanged.SummaryDifference0.3%

- Check52 days agoChange DetectedThe page now includes posted results for NCT03769467, with results reporting dates and outcome measures (ORR, DoR, PFS, OS) added to the record. This updates the study record with new efficacy and safety data beyond the initial details.SummaryDifference0.4%

- Check81 days agoChange DetectedUpgrade to version v3.2.0 with an operational status notice about potential delays and updated links; replaces the previous v3.1.0 reference.SummaryDifference2%

- Check88 days agoChange DetectedUpdate indicates a version bump from v3.0.2 to v3.1.0. No other content changes are present.SummaryDifference0.0%

Stay in the know with updates to Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.